IP Library › Granted Patent US 12,246,123
Granted Patent B2
US 12,246,123 · App. 17/464,523 · Granted Mar 11, 2025

Systems and methods for treating blood

Inventor: Patrick Richard Spearman (The Woodlands, TX)
Assignee: HUMANITY LIFE EXTENSION LLC
A61M1/369A61M1/1676A61M1/3496A61M1/1698A61M1/3633A61M2205/3368A61M2205/3606A61M2205/366
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,246,123
App. No.
17/464,523
Granted
Mar 11, 2025
Kind
B2
Abstract

According to some embodiments, a system may treat blood outside the body of a patient. The system may include one or more pumps configured to pump blood in a fluid flow path at a collective rate over 4 liters per minute. The system may include one or more heat exchangers operable to heat at least a portion of the blood to a temperature of at least 42 degrees Celsius and to allow the blood to cool one or more degrees following heating. The system may include one or more albumin dialysis modules configured to perform albumin dialysis on at least a portion of the blood at least after the one or more heat exchangers allow the blood to cool one or more degrees.

Claims (92)

1. A system comprising:

one or more pumps configured to pump blood in a fluid flow path at a collective rate between 4 and 7 liters per minute, wherein the blood was received from a patient with a core body temperature, as measured inside of the bladder, of between 42 and 43.2 degrees Celsius;

one or more heat exchangers coupled to the fluid flow path and operable to heat at least a portion of the blood to a temperature of between 42 and 45 degrees Celsius and operable to allow the blood to cool one or more degrees, following the heating of the blood to a temperature of between 42 and 45 degrees Celsius;

one or more albumin dialysis machines coupled to the fluid flow path and configured to perform albumin dialysis on at least a portion of the blood at least after the one or more heat exchangers allow the blood to cool one or more degrees; and

one or more oxygenators coupled to the fluid flow path and configured to remove carbon dioxide from at least a portion of the blood.

2. The system of claim 1 , wherein the one or more oxygenators are configured to remove carbon dioxide from at least a portion of the blood by causing the blood to flow across one side of a filter while passing a fluid over an opposite side of the filter.

3. The system of claim 1 , wherein the one or more oxygenators are configured to add oxygen to at least a portion of the blood.

4. The system of claim 1 , further comprising wherein the one or more oxygenators are coupled to the fluid flow path and configured to add oxygen to at least a portion of the blood utilizing a membrane.

5. The system of claim 1 , wherein the one or more oxygenators are configured to cause at least a portion of the heated blood to flow over at least one membrane.

6. The system of claim 5 , wherein the at least one membrane collectively has an effective surface area greater than 1.8 square meters.

7. The system of claim 1 , further comprising a tubing coupled to the fluid flow path and configured to add a substance to at least a portion of the blood, the substance facilitating the production of reactive oxygen species within the blood.

8. The system of claim 1 , further comprising one or more convection dialysis machines coupled to the fluid flow path and configured to perform convection dialysis on at least a portion of the blood at a collective rate of between 0.5 and 1.8 liters per minute.

9. The system of claim 2 , wherein the one or more oxygenators are configured to add oxygen to at least a portion of the blood.

10. The system of claim 7 wherein the substance comprises at least one of iron, copper, and ozone.

11. The system of claim 7 , wherein the substance comprises iron.

12. The system of claim 8 , wherein the one or more convection dialysis machines comprise a plurality of convection dialysis machines wherein at least one of the plurality of dialysis machines is configured to remove substances from the blood that are between 1 and 5000 Daltons in size, and wherein at least a second one of the plurality of dialysis machines is configured to remove substances from the blood between 1 and 160,000 Daltons.

13. The system of claim 8 , wherein the one or more convection dialysis machines are further configured to perform convection dialysis on a least a portion of the blood for 5-72 hours after the one or more heat exchangers allow the blood to cool one or more degrees.

14. The system of claim 8 , wherein the one or more convection dialysis machines are further configured to perform convection dialysis on a least a portion of the blood for 3-7 days after the one or more heat exchangers allow the blood to cool one or more degrees.

15. The system of claim 8 , wherein the one or more convection dialysis machines are further configured to perform convection dialysis on a least a portion of the blood for 1-7 days after the one or more heat exchangers allow the blood to cool one or more degrees.

16. The system of claim 1 , wherein the one or more albumin dialysis machines are further configured to perform albumin dialysis on at least a portion of the blood for between 8 hours and 2 days substantially continuously at least after the one or more heat exchangers allow the blood to cool one or more degrees.

17. The system of claim 1 , wherein the one or more albumin dialysis machines are further configured to perform albumin dialysis on at least a portion of the blood for between 1 and 7 days substantially continuously at least after the one or more heat exchangers allow the blood to cool one or more degrees.

18. A method comprising:

pumping blood in a fluid flow path at a rate of between 4 and 7 liters per minute wherein the blood was received from a patient with a core body temperature, as measured inside of the bladder, of between 42 and 43.2 degrees Celsius;

heating at least a portion of the blood to a temperature of between 42 and 45 degrees Celsius using one or more heat exchangers and then allowing the blood to cool one or more degrees Celsius, following the heating of the blood to a temperature of between 42 and 45 degrees Celsius;

performing albumin dialysis on at least a portion of the blood at least after the blood is allowed to cool one or more degrees; and

removing carbon dioxide from at least a portion of the blood.

19. The method of claim 18 , wherein removing carbon dioxide from at least a portion of the blood is achieved by causing the blood to flow across one side of a filter while passing a fluid over an opposite side of the filter.

20. The method of claim 18 , further comprising adding oxygen to at least a portion of the blood.

21. The method of claim 18 , further comprising using an oxygenator coupled to the fluid flow path to add oxygen to at least a portion of the blood.

22. The method of claim 18 , further comprising causing at least a portion of the heated blood to flow across at least one membrane to remove carbon dioxide.

23. The method of claim 22 , wherein the at least one membrane collectively has an effective surface area greater than 1.8 square meters.

24. The method of claim 18 , further comprising adding a substance to at least a portion of the blood, the substance facilitating the production of reactive oxygen species within the blood.

25. The method of claim 18 , further comprising performing convection dialysis on at least a portion of the blood at a collective rate of between 0.5 and 1.8 liters per minute.

26. The method of claim 19 , further comprising adding oxygen to at least a portion of the blood.

27. The method of claim 24 wherein the substance comprises at least one of iron, copper, and ozone.

28. The method of claim 24 , wherein the substance comprises iron.

29. The method of claim 25 , wherein convection dialysis is performed by a plurality of convection dialysis machines wherein at least one of the plurality of dialysis machines is configured to remove substances from the blood that are between 1 and 5000 Daltons in size wherein at least a second one of the plurality of dialysis machines is configured to remove substances from the blood between 1 and 160,000 Daltons.

30. The method of claim 25 , wherein convection dialysis is performed on a least a portion of the blood for 5-72 hours after the one or more heat exchangers allow the blood to cool one or more degrees.

31. The method of claim 25 , wherein convection dialysis is performed on a least a portion of the blood for 3-7 days after the one or more heat exchangers allow the blood to cool one or more degrees.

32. The method of claim 25 , wherein convection dialysis is performed on a least a portion of the blood for 1-7 days after the one or more heat exchangers allow the blood to cool one or more degrees.

33. The system of claim 18 , wherein albumin dialysis is performed on at least a portion of the blood for between 8 hours and 2 days substantially continuously at least after the one or more heat exchangers allow the blood to cool one or more degrees.

34. The method of claim 18 , wherein albumin dialysis on at least a portion of the blood for between 1 and 7 days substantially continuously at least after the one or more heat exchangers allow the blood to cool one or more degrees.

35. The method of claim 18 , further comprising adding a chemotherapeutic substance to at least a portion of the blood.

36. The method of claim 18 , wherein carbon dioxide is removed from at least a portion of the blood substantially continuously for a period of between thirty minutes and eight hours.

37. The method of claim 18 , further comprising adding electrolyte balanced fluid to at least a portion of the blood at a rate between 7 and 30 liters per hour.

38. The method of claim 37 , wherein the electrolyte balanced fluid is added to at least a portion of the blood at a rate between 7 and 30 liters per hour for between 30 minutes and 6 hours.

39. The method of claim 18 , wherein the blood is pumped in the fluid flow path at the rate of between 4 and 7 liters per minute for between 30 minutes and 6 hours.

40. A method for treating cancer comprising:

removing blood from the human body through a fluid flow path at a rate of between 4 and 7 liters per minute;

heating at least a portion of the blood outside of the human body;

returning at least a portion of the blood to the human body after heating the blood outside of the human body;

wherein the human body is heated to a core temperature of between 42 and 43.2 degrees Celsius for between 30 minutes and 6 hours;

causing the core temperature of the human body to drop below 42 degrees Celsius following the heating of the core temperature of between 42 and 43.2 degrees Celsius;

performing albumin dialysis on at least a portion of the blood outside of the human body at least after the core temperature of the human body drops below 42 degrees Celsius following the heating of the core temperature of between 42 and 43.2 degrees Celsius; and

removing carbon dioxide from at least a portion of the blood.

41. The method of claim 40 , wherein removing carbon dioxide from at least a portion of the blood is achieved by causing the blood to flow across one side of a filter while passing a fluid over an opposite side of the filter.

42. The method of claim 40 , further comprising adding oxygen to at least a portion of the blood.

43. The method of claim 40 , further comprising using an oxygenator coupled to the fluid flow path to add oxygen to at least a portion of the blood.

44. The method of claim 40 , further comprising causing at least a portion of the heated blood to flow across at least one membrane to remove carbon dioxide.

45. The method of claim 44 , wherein the at least one membrane collectively has an effective surface area greater than 1.8 square meters.

46. The method of claim 40 , further comprising adding a substance to at least a portion of the blood, the substance facilitating the production of reactive oxygen species within the blood.

47. The method of claim 40 , further comprising performing convection dialysis on at least a portion of the blood at a collective rate of between 0.5 and 1.8 liters per minute.

48. The method of claim 41 , further comprising adding oxygen to at least a portion of the blood.

49. The method of claim 46 wherein the substance comprises at least one of iron, copper, and ozone.

50. The method of claim 46 , wherein the substance comprises iron.

51. The method of claim 47 , wherein convection dialysis is performed by a plurality of convection dialysis machines wherein at least one of the plurality of dialysis machines is configured to remove substances from the blood that are between 1 and 5000 Daltons in size wherein at least a second one of the plurality of dialysis machines is configured to remove substances from the blood between 1 and 160,000 Daltons.

52. The method of claim 47 , wherein convection dialysis is performed on a least a portion of the blood for 5-72 hours after the one or more heat exchangers allow the blood to cool one or more degrees.

53. The method of claim 47 , wherein convection dialysis is performed on a least a portion of the blood for 3-7 days after the one or more heat exchangers allow the blood to cool one or more degrees.

54. The method of claim 47 , wherein convection dialysis is performed on a least a portion of the blood for 1-7 days after the one or more heat exchangers allow the blood to cool one or more degrees.

55. The system of claim 40 , wherein albumin dialysis is performed on at least a portion of the blood for between 8 hours and 2 days substantially continuously at least after the one or more heat exchangers allow the blood to cool one or more degrees.

56. The method of claim 40 , wherein albumin dialysis on at least a portion of the blood for between 1 and 7 days substantially continuously at least after the one or more heat exchangers allow the blood to cool one or more degrees.

57. The method of claim 40 , further comprising adding a chemotherapeutic substance to at least a portion of the blood.

58. The method of claim 40 , wherein carbon dioxide is removed from at least a portion of the blood substantially continuously for a period of between thirty minutes and eight hours.

59. The method of claim 40 , further comprising adding electrolyte balanced fluid to at least a portion of the blood at a rate between 7 and 30 liters per hour.

60. The method of claim 59 , wherein the electrolyte balanced fluid is added to at least a portion of the blood at a rate between 7 and 30 liters per hour for between 30 minutes and 6 hours.

61. The method of claim 40 , wherein the blood is pumped in the fluid flow path at the rate of between 4 and 7 liters per minute for between 30 minutes and 6 hours.

62. The method of claim 40 , further comprising providing the human body with a dose of iron such that the blood of the human body contains increased amounts of iron as compared to prior to receiving the dose of iron.

63. The method of claim 41 , further comprising providing the human body with a dose of iron such that the blood of the human body contains increased amounts of iron as compared to prior to receiving the dose of iron.

64. The method of claim 42 , further comprising providing the human body with a dose of iron such that the blood of the human body contains increased amounts of iron as compared to prior to receiving the dose of iron.

65. The method of claim 43 , further comprising providing the human body with a dose of iron such that the blood of the human body contains increased amounts of iron as compared to prior to receiving the dose of iron.

66. The method of claim 44 , further comprising providing the human body with a dose of iron such that the blood of the human body contains increased amounts of iron as compared to prior to receiving the dose of iron.

67. The method of claim 45 , further comprising providing the human body with a dose of iron such that the blood of the human body contains increased amounts of iron as compared to prior to receiving the dose of iron.

68. A system comprising:

one or more pumps configured to pump blood in a fluid flow path at a collective rate between 4 and 7 liters per minute;

an oxygenator coupled to the fluid flow path and configured to add oxygen to at least a portion of the blood;

one or more heat exchangers coupled to the fluid flow path for heating at least a portion of the blood and causing a human body receiving the heated blood to have a core temperature of between 42 and 45 degrees Celsius for between 15 minutes and 7 hours; and

one or more albumin dialysis machines coupled to the fluid flow path operable to performing albumin dialysis on at least a portion of the blood for a period of time after the heating means has reduced or stopped heating the blood such that the core temperature of the human body drops below 42 degrees Celsius.

69. The system of claim 68 wherein the period of time is 5-72 hours.

70. The system of claim 68 wherein the period of time is 48-72 hours.

71. The system of claim 68 wherein the period of time is 1-7 days.

72. The system of claim 68 wherein the period of time is 3-7 days.

73. The system of claim 68 wherein the period of time is 1-8 days.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2021
From: SPEARMAN, PATRICK RICHARD
To: HUMANITY LIFE EXTENSION LLC
Reel/Frame 057361/0430 →
Continuity (2)
Continuation 16214840 · Dec 10, 2018
Related Publication 20210393866A1 · Dec 23, 2021
References Cited (69)
US 3769977A · Brumfield · 1973 [cited by applicant]
US 5080796A · Nose' · 1992 [cited by examiner]
US 5476444A · Keeling · 1995 [cited by applicant]
US 5647984A · Hovland · 1997 [cited by applicant]
US 5725776A · Kenley · 1998 [cited by applicant]
US 5730720A · Sties · 1998 [cited by applicant]
US 6156007A · Ash · 2000 [cited by applicant]
US 6579496B1 · Fausset · 2003 [cited by applicant]
US 6827898B1 · Fausset · 2004 [cited by applicant]
US 7819835B2 · Landy · 2010 [cited by applicant]
US 7998101B2 · Ash · 2011 [cited by applicant]
US 8496874B2 · Gellman · 2013 [cited by applicant]
US 9555184B2 · Spearman · 2017 [cited by applicant]
US 10773012B2 · Spearman · 2020 [cited by applicant]
US 10946134B2 · Spearman · 2021 [cited by applicant]
US 11033673B2 · Spearman · 2021 [cited by applicant]
US 11147907B2 · Spearman · 2021 [cited by examiner]
US 11219709B2 · Spearman · 2022 [cited by applicant]
US 11344662B2 · Spearman · 2022 [cited by applicant]
US 20010039441A1 · Ash · 2001 [cited by applicant]
US 20030163183A1 · Carson · 2003 [cited by applicant]
US 20040102732A1 · Naghavi · 2004 [cited by applicant]
US 20080199357A1 · Gellman · 2008 [cited by applicant]
US 20100198132A1 · Pesenti · 2010 [cited by applicant]
US 20100326916A1 · Wrazel et al. · 2010 [cited by applicant]
US 20120189711A1 · Greenberg · 2012 [cited by applicant]
US 20120296253A1 · Matthews et al. · 2012 [cited by applicant]
US 20150231322A1 · Spearman · 2015 [cited by examiner]
US 20150231323A1 · Spearman · 2015 [cited by applicant]
US 20150231324A1 · Spearman · 2015 [cited by applicant]
US 20150306297A1 · Linden · 2015 [cited by examiner]
US 20170246375A1 · Spearman · 2017 [cited by applicant]
US 20190175813A1 · Spearman · 2019 [cited by applicant]
US 20200179586A1 · Spearman · 2020 [cited by applicant]
AU 2013349977B2 · 2013 [cited by applicant]
DE 4406106A1 · 1995 [cited by applicant]
EP 1490129B1 · 2003 [cited by applicant]
EP 3107642 · 2019 [cited by applicant]
WO 2016398366A1 · 2017 [cited by applicant]
WO 2017158392A1 · 2017 [cited by applicant]
WO 2018144970A1 · 2018 [cited by applicant]
Communication pursuant to Article 94(3) EPC; Application No. 19 214 835.1-1113; dtd Oct. 24, 2022. [cited by applicant]
Communication pursuant to Article 94(3) EPC; Application No. 19 214 835.1-1113; dtd Nov. 11, 2023. [cited by applicant]
Communication from EPO re: Appin No. 18748028.0-1113/3648814; PCT/US2018016797; dtd Mar. 9, 2021. [cited by applicant]
Examination Report (Intellectual Property India) re: Application No. 201924047806; dtd Jan. 13, 2023; 7 pages. [cited by applicant]
Examination Report (Intellectual Property India) re: Application No. 201924047808; dtd Feb. 2, 2023; 6 pages. [cited by applicant]
Extended European Search Report; Application No. 22166859.3-1113; dtd Jul. 21, 2022. [cited by applicant]
U.S. Appl. No. 16/214,728 filed Dec. 10, 2019 (P.R. Spearman). [cited by applicant]
U.S. Appl. No. 16/214,807 filed Dec. 10, 2018 (P.R. Spearman). [cited by applicant]
Rehydration Project, “Unit 5—Treatment of Dehydrated Patients Medical Education: Teaching Medical Students about Diarrhoeal Diseases”, Meded, Aug. 2, 2013; pp. 4-5; downloaded from internet via internet archive—waybackm… [cited by applicant]
Forster et al., “Low-flow CO2 removal integrated into a renal-replacement circuit can reduce acidosis and decrease vasopressor requirements”, Critical Care 2013, 17:R154, p. 1, results [downloaded from internet: http://… [cited by applicant]
Joseph B. Zwischenberger, et al. “Percutaneous Venovenous Perfusion-Induced Systemic Hyperthermia for Lung Cancer: A Phase I Safety Study”, Ann Thorac Surg 2004; 77:1916-1925 2004. [cited by applicant]
PCT—Notification of Transmittal of the International Search Report and the Written Opinion of the Int'l Searching Authority, or the Declaration, for Int'l Appl. No. PCT/US15/16064, Int'l filing date Feb. 16, 2015 Feb. 1… [cited by applicant]
PCT Recordation of Search History, Ref. Appl. PCT/US15/16064; CLIN Number/Technical Field of PCT Application: 0002 Life Sciences Jun. 14, 2015. [cited by applicant]
PCT; International Search Report and Written Opinion of the International Searching Authority (PCT Rule 43 bis. 1), PCT Article 18 and Rules 43 and 44), Intl. Appln. No. PCT/US 18/16797; Apr. 12, 2018. [cited by applicant]
European Patent Office Communication pursuant to Rule 62 EPC, the supplementary European search report (Art. 153(7) EPC) and the European search opinion, Application No. 15749068.1-1651/3107642 PCT/US2015016064; Ref. P1… [cited by applicant]
European Patent office Communication pursuant to Article 94(3) EPC, Application No. 15749068.1-1115; Ref. P12027WE Jul. 8, 2018. [cited by applicant]
Spearman, U.S. Appl. No. 14/623,447 Non-final Office Action. Apr. 4, 2018. [cited by applicant]
Spearman, U.S. Appl. No. 14/623,447 Response to Non-final Office Action. Aug. 3, 2018. [cited by applicant]
Spearman, U.S. Appl. No. 14/623,455 Final Office Action. Sep. 25, 2018. [cited by applicant]
EPO Communication; extended European search report; Appln. 19214835.1-1115 (Ref. P12785EP/JCM/cf) Apr. 5, 2020. [cited by applicant]
Spearman, U.S. Appl. No. 14/623,455: Non-Final Office Action Feb. 22, 2018. [cited by applicant]
Spearman, U.S. Appl. No. 14/623,455: Response to Non-Final Office Action May 22, 2018. [cited by applicant]
PCT Intl Search Report re PCT/US15/16064; Jul. 8, 2015. [cited by applicant]
Spearman, U.S. Appl. No. 14/623,455: RCE Response Jan. 25, 2019. [cited by applicant]
Spearman, U.S. Appl. No. 14/623,455: Non-Final Office Action Feb. 21, 2019. [cited by applicant]
Spearman, U.S. Appl. No. 14/623,455: Response to Non-Final Office Action Jun. 21, 2019. [cited by applicant]
Spearman, U.S. Appl. No. 14/623,447 Non-Final Office Action Mar. 4, 2019. [cited by applicant]
Examination Report (Intellectual Property India) re: Application No. 201924047805; dtd Nov. 16, 2022; 8 pages. [cited by applicant]